Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04485156 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

Study acronym: Hi-DoRi-3
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 24, 2020 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to investigate the effectiveness and safety of the regimen including high dose rifampicin for individualized duration (3 months after Culture Conversion) for the treatment of drug-sensitive pulmonary tuberculosis.
Trial Details
NCT Number NCT04485156
Lead Sponsor Seoul National University Hospital
Collaborators: Chonnam National University Hospital, National Medical Center, Seoul, Pusan National University Hospital, Pusan National University Yangsan Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Severance Hospital, Korean Institute of Tuberculosis, International Tuberculosis Research Center, Korean Center for Disease Control and Prevention
Conditions Tuberculosis, Pulmonary
Enrollment 926 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov